Midomafetamine
Phase 3Small molecule
Midomafetamine is a small molecule that works as a Sodium-Dependent Dopamine Transporter Releasing Agent; Sodium-Dependent Noradrenaline Transporter Releasing Agent; Sodium-Dependent Serotonin Transporter Releasing Agent.[2] It is being investigated across 14 indications, with its most advanced program in Phase 3.[1]
Midomafetamine is one of 330 small molecule programs targeting Methamphetamine Dependence. It is currently in Phase 3.
14
Indications
23
Total Trials
2
Active Trials
329
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Midomafetamine
LLykos Therapeutics
Phase 3
Celexa
AbbViePreclinical
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Zocor
OOrganon and Co
Preclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment6 trials
PTSD5 trials
Dose Optimization of MDMA-Assisted Therapy for PTSD
Recruiting·—·Phase 2·NCT06418178·60 enrolled
Anxiety2 trials
Methamphetamine2 trials
7 more indications
Post-Traumatic Stress Disorder1 trial
Double-blind1 trial
Moderate Hepatic Impairment1 trial
Chronic PTSD1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Midomafetamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Sodium-Dependent Dopamine Transporter Releasing Agent; Sodium-Dependent Noradrenaline Transporter Releasing Agent; Sodium-Dependent Serotonin Transporter Releasing Agent[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLykos Therapeutics